Jenkem Technology Co

Jenkem Technology Co EBITDA per Share

The EBITDA per Share of Jenkem Technology Co (688356.SS) as of Oct 20, 2026 is 1.20 CNY. In the previous year, EBITDA per Share was 0.82 CNY — a change of 45.65% (higher).

EBITDA per Share

1.20CNY

YoY

45.65%

Last updated:

EBITDA per Share of Jenkem Technology Co is 2025 1.20 CNY. EBITDA per Share of Jenkem Technology Co was 2024 0.82 CNY. It decreases by 45.65% higher compared to the previous year.

The Jenkem Technology Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
0.76 CNY
Jan 1, 2019
1.65 CNY
Jan 1, 2020
1.74 CNY
Jan 1, 2021
3.38 CNY
Jan 1, 2022
3.65 CNY
Jan 1, 2023
2.34 CNY
Jan 1, 2024
0.82 CNY
Jan 1, 2025
1.20 CNY
The Jenkem Technology Co EBITDA per Share history
YEAREBITDA per ShareYoY
1.20CNY+45.65%
0.82CNY-64.84%
2.34CNY-35.90%
3.65CNY+7.99%
3.38CNY+94.61%
1.74CNY+5.34%
1.65CNY+117.19%
0.76CNY+63.22%
0.46CNY+201.62%
0.15CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jenkem Technology Co Stock analysis

What does Jenkem Technology Co do? Jenkem Technology Co., Ltd. generates revenue through the research, development, production, and sales of medical polyethylene glycol (PEG) and its active derivatives. The company's primary products are sold to pharmaceutical companies, research institutions, and medical device manufacturers that use these materials in drug development and production. Technical services such as patent and non-patent technology licensing, as well as R&D services, also contribute to the company's income. The firm's customer segments include entities involved in drug research, development, and production, as well as scientific research organizations. The company's business model focuses on providing specialized materials and technical support for the medical and pharmaceutical sectors. Medical polyethylene glycol and its active derivatives serve as critical components in various medical applications, driving demand from industry partners. By offering both physical products and intellectual property services, Jenkem Technology diversifies its revenue streams within the healthcare technology space. Jenkem Technology Co., Ltd. operates with a clear focus on the medical and pharmaceutical industries, targeting clients that require high-quality PEG-based materials for their research and manufacturing processes. The company's technical services, including licensing and R&D support, further strengthen its position as a supplier of essential materials and solutions in the healthcare sector. Jenkem Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jenkem Technology Co stock

EBITDA per Share of Jenkem Technology Co is 1.20 CNY in 2025.

EBITDA per Share of Jenkem Technology Co changed from 0.82 CNY to 1.20 CNY, representing a 45.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Jenkem Technology Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Jenkem Technology Co

All Key Metrics — Jenkem Technology Co